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Abstract 
Oral surgery in patients with bleeding disorders is associated with a high risk of 
bleeding during and after surgery. This article is aimed to present the case of an 
eight-year-old girl suffering from severe Fanconi anemia with pancytopenia who 
underwent a dental extraction. The hemostatic effect of local administration of 
tranexamic acid in combination with a primary suture seems to be extremely help-
ful in order to reduce the necessity of blood products and the risk of postoperative 
bleeding. 
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INTRODUCTION  
Fanconi anemia (FA) is a rare autosomal re-
cessive disorder characterized by congenital 
malformations, progressive bone marrow hy-
poplasia, and a high risk of malignancies. The 
existing literature describes occurrence fre-
quency of FA with approximately 1:360,000 
[1] with a female-to-male ratio of 1:2 [2]. Fif-
teen genetic subtypes can be distinguished: 
FA-A, -B, -C, -D1, -D2, -E, -F, -G, -I, -J, -L, -
M, -N, -O, and –P. The majority of FA pa-
tients (∼85%) belong to subtypes A (∼60%), 
C (∼10–15%), or G (∼10%), while a minority 
(∼15%) is distributed over the remaining 12 
subtypes [3]. Cells of FA patients are charac-
teristically sensitive to chromosome breakage 
by DNA cross-linking agents [4]. 
The diagnosis is usually made between the age 
of 5 and 10 years [5]. Whereas, one third of 
the affected patients do not have any obvious 
abnormalities, in the majority of cases, physi-
cal signs, such as abnormal skin pigmentation, 
short stature, thumb and radial anomalies, 
structural renal defects, microcephaly, and de-
layed development are recognizable at birth 
and during early childhood.  
The most frequent oral manifestations are gin-
givitis, periodontitis, rotated teeth, and dental 
agenesis [6]. The high prevalence of periodon-
tal diseases and gingivitis may be related to 
frequent immune system deficiencies, anemia 
and leukopenia. However, patients affected by 
FA often display deficits in their oral hygiene 
as well [7]. 
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Furthermore, they are predisposed to the de-
velopment of squamous cell carcinoma (SCC), 
especially in the oral cavity [8].  
Many FA patients experience bone marrow 
failure, which is generally characterized by an 
increasing pancytopenia, often initially with 
thrombocytopenia or leukopenia. In general, 
bone marrow transplantation is currently the 
most effective treatment to cure severe aplas-
tic anemia or acute myeloid leukemia and the 
myelodysplastic syndrome [9]. All patients 
designated for transplantation should be ex-
amined for presence of any active infection. 
Dentists should carefully exam the oral situa-
tion within the pre-transplant evaluation. De-
cayed teeth have to be restored and destroyed 
teeth must be removed before transplantation.  
It is difficult to find the optimal management 
for patients with FA when they need oral sur-
gery, because of their susceptibility to infec-
tions and pancytopenia. The following report 
discusses the management of such a patient, 

























The patient was an eight-year-old Syrian girl 
(body weight, 28 kilograms; body height, 127 
centimeters).  
Diagnosed with FA, she was referred to our 
clinic to evaluate her dental health before 
planning bone marrow transplantation. Her 
parents and her siblings (9- and 11-year-old 
brothers) were not affected by the disease.  
The physical examination showed a young girl 
with clinical signs of FA including skin hypo-
pigmented areas, hypertrichosis, scoliosis, ab-
normal ribs and multiple hematomas in the 
region of the thighs (Fig 1).  
The hexadactyly of her left hand was surgical-
ly corrected three months after birth. The oral 
examination revealed several decayed teeth 
(Fig 2 and 3).  
In the lower jaw 74, 75, 84 and 85 were totally 
destroyed by caries and therefore, indicated 
for extraction.  
The results of the laboratory tests are men-
tioned in Table 1.  
 
 
Fig 1. Physical examination: skin hypopigmented areas and hypertrichosis. Photograph of the entire 
body of the patient shows scoliosis. 
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The most noticeable aspect was the severe 
thrombocytopenia (5,000/µL). A mild hyper-
sensitivity reaction after platelet transfusion in 
the past was recorded in her file. 
Preparation of dental treatment was carried out 
in close cooperation with the Hemotology On-
cology Unit of our hospital. Due to the FA re-
lated severe thrombocytopenia, a platelet con-
centrate was necessary to raise the platelet 
count above 50,000/µL. After the intravenous 
(IV) premedication with 50 mg glucocorticoid 
(prednisolone) and 3 mg antihistaminic agent 
(dimetinden), which was required to avoid 
another transfusion reaction, a single unit of 
leuko-depleted and irradiated apheresis plate-
lets, was given intravenously. A platelet count 
of 75,000/µL was achieved. The treatment was 
performed under general anesthesia to avoid 
age-related noncompliance. Prophylactic anti-
biotic treatment using 1.5 g ampicil-
lin/sulbactam IV (ampicillin HEXAL® comp, 
Hexal, Holzkirchen, Germany) was given to 
























A buccal infiltration using a total of 2.0 mL of 
4.0% articain with adrenaline 1:200,000 (Ul-
tracain D-S, Sanofi-Aventis, Paris, France) 
was conducted for local anaesthesia.  
We started with the restorative treatment of 
teeth 54, 65, 16, 26, 36 and 46.  
Following that, 74, 75, 84 and 85 were ex-
tracted. The sockets were immediately cov-
ered with tranexamic acid (TA) (Cyklokapron, 
Meda Pharma, Bad Homburg, Germany) and 
closed with a 4x0 resorbable suture (Vicryl, 
Ethicon Johnson & Johnson, New Brunswick, 
USA) (Fig 4 and 5).  
Gauzes saturated with TA were placed onto 
the teeth sockets for five minutes. Following 
this protocol, an excellent hemostasis was 
achieved. The patient was kept in hospital for 
observation. Gauzes saturated with TA were 
applied for local hemostasis during the follow-
ing three days to avoid any late postoperative 
bleeding caused by early fibrinolysis and 
hyperfibrinolysis, Postoperative pain was con-












Fig 2. Panoramic radiograph before dental treatment 
 
Fig 3. Preoperative photograph. Teeth number 
74 and 75 are completely destroyed. 
 
 Reference range Findings 
White blood cells 4,3-11,4x103/µL 2,0x103/µL 
Red blood cells 3,9-5,0x106/µL 3,5*106/µL 
Hemoglobin 6,6-8,2 mmol/L 6,3 mmol/L 
Hematocrit 0,32-0,40 0,28 
Platelets 150.000-400.000/µL 5.000/µL 
INR 0,8-1,2 0,9 
Partial thromboplastin time 30-50 s 35 s 
 
Table 1. Laboratory Findings 
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The diet (consisted of cool liquids followed by 
semi-solid food for 3 days after operation. No 
postoperative bleeding appeared during the 
observational period. 
The platelet count was observed after surgery. 
No further blood products were necessary de-




The predominant symptom of FA is the pro-
gressive bone marrow failure usually during 
early childhood with increasing pancytopenia, 
often initial with thrombocytopenia or leuko-
penia. Because of the important role of plate-
lets in hemostasis in forming the initial plug in 
vessel injuries, severe thrombocytopenia 
presents a high risk for a postoperative he-
morrhage after dental extraction in these pa-
tients.  
The threshold platelet count for thrombocyto-
penic patients who have to undergo surgical 
procedures remains unclarified in the current 
literature. It is however, common practice to 
increase the platelet count to at least 
50,000/µL. For procedures in critical regions, 
such as the brain or eyes and for major sur-
gery, the platelet count should be raised to at 


















Obtaining a post transfusion platelet count is 
required before starting surgery. Depending on 
the expected level of hemorrhage, additional 
platelet concentrates can be transfused intra-
operatively and postoperatively [11]. In addi-
tion, the use of local hemostatic measures is 
necessary to reduce the need of blood products 
and the risk of postoperative bleeding. We 
used TA, a synthetic derivative of the amino 
acid lysine that causes an antifibrinolytic ac-
tivity in humans. It reversibly attaches to the 
lysine-binding site of plasminogen and blocks 
the binding to fibrin as well as its activation 
and transformation to plasmin. Thereby, the 
fibrinolysis and blood clot degradation is re-
tarded [12]. In some countries, TA is not 
available. Epsilon aminocaproic acid (EA) has 
a similar effect. However, EA exhibits a 
slightly shorter plasma half-life and shows less 
antifibrinolytic activity than TA [13]. Various 
reports referred to the successful local use of 
TA in order to reduce oral bleeding and the 
need of blood products after oral surgery in 
patients with bleeding disorders [14,15]. Other 
local measures such as collagen fleece [16], 
oxidized cellulose [17], gelatin sponge [11], 
fibrin glue [18] and cyanoacrylate [19] are al-
so reported to be helpful for local hemostasis. 
Furthermore, these measures may be com-
  
Fig 5. Perioperative photograph. The teeth sockets 
74 and 75 after elevation and flooded with TA. 
 
Fig 4. Immediate postoperative photograph. The 
sockets are closed with resorbable suture 
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bined with antifibrinolytic drugs to potentiate 
the hemostatic effect. In addition, systemic EA 
or TA may be used if local hemostasis and 
platelet transfusion appear inadequate. A load-
ing dose of 10 g intravenous followed by 1 g/h 
is recommended to achieve an effective plas-
ma concentration [11]. In order to prevent 
secondary bleeding, resorbable suture material 
was used to avoid suture removal. Non-
steroidal, anti-inflammatory drugs and aspirin, 
which inhibit the platelet function, must be 
avoided for pain control. Paracetamol is a safe 
alternative to prevent postoperative pain.  
There are successful treatment protocols in the 
current literature for patients affected by 
thrombocytopenia. Engel et al. [16] describe 
the successful management of a female FA 
patient undergoing bone grafting and dental 
implant placement. The platelet count in this 
case was 25,000/µL. The patient received 1 U 
of single donor platelets preoperatively. EA 
was given via continuous infusion during the 
procedure at the rate of 500 mg/h. Additional 
pooled platelets and packed red blood cells 
were given intraoperatively. After taking the 
graft from the anterior iliac crest they used 
collagen fleece for local hemostasis. Two units 
of fresh frozen plasma were given postopera-
tively and the EA infusion was continued at 
500 mg/h for 8 hours. A total blood loss of 
1,000 mL was registered. Because of a platelet 
count of 64,000/µL, no blood products were 
necessary for the abutment placement in the 
mandible after 4 months and the maxilla after 
8 months. The patient received only 500 mg 
EA orally, every 6 hours starting the day be-
fore the procedure and continuing 2 days post-
operatively. All implants were noted to have 
solid osseointegration without difficulty and 
with adequate hemostasis.  
Henderson et al. [11] reported three treatment 
protocols for patients with thrombocytopenia 
undergoing dental extraction. Platelet transfu-
sions were combined in one case with gelatin 
sponge for local hemostasis. In all cases, the 
surgical sites were closed primarily.  
One patient presented postoperative hemorr-
hage, which was managed systemically with 
multiple transfusions of packed red blood cells 
and platelets and topically with thrombin-
soaked gauze over the surgical sites as an ad-
junctive hemostatic measure. This is an indica-
tion that postoperative bleeding after oral sur-
gery in patients exhibiting thrombocytopenia 
is difficult to predict, even though defined 
treatment protocols are used. Postoperative 
monitoring of these patients is required to pre-
vent excessive hemorrhage. 
While the risk for hematologic diseases is 
greater during early childhood, solid tumors, 
particularly SCC, are most frequently ob-
served in adults [4,20].  
SCC in FA patients develops earlier than in 
the general population and shows a more ag-
gressive behavior [4]. An average age of 27 
years in FA patients (21) and an average time 
between the age of FA diagnosis and cancer 
development of 10.5 years [22] have been re-
ported in the literature. The commonest locali-
zations of SCC in FA patients in descending 
order are: the tongue, anogenital region, pha-
rynx, larynx, oral mucosa, mandible and skin 
[23].  
There are indications that the incidence of ma-
lignancy development is greater after FA pa-
tients have endured bone marrow transplanta-
tion, maybe by adding risk factors, such as 
pre-transplantation conditioning with chemo-
therapy and radiotherapy, immunosuppressive 
agents given for prophylaxis of graft versus 
host disease (GVHD) and GVHD itself [23]. 
Concerning the high risk of development ma-
lignancies, a biannual screening of the oral 
cavity and oropharynx starting between the 
ages of 15 and 20 is recommended. FA pa-
tients with a history of leukoplakia or recur-
rent oral lesions should be followed every six 
or eight weeks [4]. If malignancies are diag-
nosed, operative procedures in FA patients 
with head and neck cancer are similar to the 
general population with similar pathologies 
[24,25].  
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The associated bone marrow failure in FA pa-
tients requires preoperative consultation in a 
Hematology Oncology Treatment Centre. The 
need of blood and platelet transfusion before 
surgery must be considered [24]. Besides the 
risk of development of wound infections and 
hematoma, FA patients can have serious prob-
lems in adjuvant therapy [4,26]. Because of 
the increased susceptibility to mutagenic sti-
muli [27], standard doses of radiotherapy and 
chemotherapy are generally reduced [24]. 
 
CONCLUSION 
The topical administration of TA in combina-
tion with primary suture and perioperative 
transfusion of platelets seems to be effective in 
the prevention of postoperative hemorrhage in 
patients with severe thrombocytopenia under-
going dental extraction. It is essential to fol-
low defined surgical protocols in the manage-
ment of patients with bleeding disorders. A 
specialized dental service should perform 
these procedures in close cooperation with a 
hematology oncology treatment centre. The 
high risk of developing an oral squamous cell 
carcinoma for patients affected by FA, re-
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